Sertraline + Levetiracetam + Placebo
Phase 2/3Terminated 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive-Compulsive Disorder
Conditions
Obsessive-Compulsive Disorder
Trial Timeline
Nov 1, 2005 → Apr 1, 2008
NCT ID
NCT00299611About Sertraline + Levetiracetam + Placebo
Sertraline + Levetiracetam + Placebo is a phase 2/3 stage product being developed by UCB for Obsessive-Compulsive Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00299611. Target conditions include Obsessive-Compulsive Disorder.
What happened to similar drugs?
2 of 4 similar drugs in Obsessive-Compulsive Disorder were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
15
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00299611 | Phase 2/3 | Terminated |
Competing Products
8 competing products in Obsessive-Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 35 |
| pregabalin + Placebo | Pfizer | Approved | 43 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 44 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 39 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 34 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 34 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 32 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 32 |